Suppr超能文献

β2微球蛋白:重新评估

beta2-Microglobulin: a reevaluation.

作者信息

Bach M L, Lindahl K F, Poulik M D

出版信息

Fed Proc. 1976 Apr;35(5):1188-91.

PMID:57073
Abstract

Rabbit antiserum to human beta2-microglobulin was used to inhibit the proliferative response of lymphocytes in a variety of in vitro assays and to block the effector phase of the cell mediated lympholysis reaction. The antiserum was able to inhibit both of these reactions; it is not clear whether the cytotoxic reaction that we are studying in a xenogeneic human-rabbit system is based on phytohemagglutinin dependent cytotoxicity or on specific recognition of target cells by receptors on the effector cells, or most likely on a combination of both cytotoxic mechanisms. Whereas the possibility that beta2-microglobulin may be associated with receptors on the thymus-derived lymphocyte surface is considered, it is also pointed out that the effect of the antiserum may be based on other mechanisms of perturbing the membrane so as to inhibit these responses.

摘要

用人β2-微球蛋白的兔抗血清在多种体外试验中抑制淋巴细胞的增殖反应,并阻断细胞介导的淋巴细胞溶解反应的效应阶段。该抗血清能够抑制这两种反应;目前尚不清楚我们在异种人-兔系统中研究的细胞毒性反应是基于植物血凝素依赖性细胞毒性,还是基于效应细胞上的受体对靶细胞的特异性识别,或者最有可能是基于这两种细胞毒性机制的组合。虽然考虑了β2-微球蛋白可能与胸腺来源的淋巴细胞表面受体相关的可能性,但也指出抗血清的作用可能基于干扰膜的其他机制,从而抑制这些反应。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验